Jennifer Jackson, Ph.D. is the Director of Translational Science and Strategy at Personal Genome Diagnostics (PGDx). Jennifer has over 15 years of oncology-focused research and industry experience including 8 years focused on liquid biopsy in the clinical setting. She received her B.S from the University of Florida and her Ph.D. in Biochemistry and Molecular Biology from Emory University School of Medicine. During her postdoctoral appointment in the Department of Surgery at Boston University Medical Center, her training focused on assessing the clinical utility of ctDNA as a biomarker for early detection of cancer and monitoring of minimal residual disease in response to therapy using digital PCR and next-generation sequencing (NGS). Following her postdoctoral training, she joined RainDance Technologies and later, Bio-Rad Laboratories as a Global Market Development Scientist and served as a trusted advisor to the company and to the customer base to facilitate market access and scientific success. Since 2017, Dr. Jackson has brought her expertise in precision medicine to PGDx to support the goals of driving clinical expansion and uptake of NGS, building industry partnerships and academic collaborations, and helping to advance new applications within oncology diagnostics.
Clinical Dx showcase:
Personal Genome Diagnostics (PGDx)
Personal Genome Diagnostics (PGDx) is Empowering the Fight Against Cancer by unlocking actionable information from the genome. We are developing an innovative portfolio of regulated tissue-based and non-invasive liquid biopsy genomic products for laboratories worldwide.
Enabling Precision Oncology through Decentralized NGS-based Solutions
Personal Genome Diagnostics is empowering the fight against cancer by unlocking actionable information from the genome. We have developed an innovative and comprehensive portfolio of RUO and IVD tissue-based and non-invasive liquid biopsy genomic profiling solutions for use in laboratories worldwide.
The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative